Nuvalent, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company was acquired and taken private, ending its time as an independent public company for shareholders.
Annual meeting results show shareholders voted on company leadership and compensation decisions that affect the business.
A buyer offered to purchase all shares, giving shareholders a chance to sell at a set price per share.
First-quarter earnings show how the company performed financially and help investors track progress.
Approval of this lung cancer drug could create revenue and growth, making the company more valuable.
Annual report details all year's earnings, expenses and strategy, helping investors understand total performance.
Stocky reads Nuvalent, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Nuvalent, Inc.'s most recent tracked filing was a 8-K on 15 Jul 2026: Merger completed, company becomes wholly owned subsidiary.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.